Fatty acid receptors as new therapeutic targets for diabetes.
about
Transient Receptor Potential Channel Type M5 Is Essential for Fat TasteMetabolic shifts due to long-term caloric restriction revealed in nonhuman primatesMercaptoacetate and fatty acids exert direct and antagonistic effects on nodose neurons via GPR40 fatty acid receptorsMagnificent seven: roles of G protein-coupled receptors in extracellular sensing in fungi.Adhesion GPCRs are widely expressed throughout the subsections of the gastrointestinal tract.Na/K-ATPase assay in the intact mice lung subjected to perfusionDiscovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics.A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse isletActivation of oral trigeminal neurons by fatty acids is dependent upon intracellular calciumSeven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects.Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in miceThe fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening.Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.Endogenous metabolites as ligands for G protein-coupled receptors modulating risk factors for metabolic and cardiovascular disease.Fasiglifam as a new potential treatment option for patients with type 2 diabetes.Lipid metabolism, apoptosis and cancer therapy.Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3.Allosteric rescuing of loss-of-function FFAR2 mutations.Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.Discovery of the First Environment-Sensitive Fluorescent Probe for GPR120 (FFA4) Imaging.Novel computational methodologies for structural modeling of spacious ligand binding sites of G-protein-coupled receptors: development and application to human leukotriene B4 receptor.
P2860
Q22336988-622E5E56-458B-4338-B9CD-9824187A3AAFQ24647414-1C53A2F6-1360-4AD3-9902-04CC08329023Q34121932-F3FA40C1-64EB-4AF6-8B2E-48DC61C697A9Q34386803-60180A71-6166-4A89-A153-9CF807DB2949Q34420848-466BFB4E-18A0-4917-AB67-5DD5177BB654Q34566015-70858174-574D-45E6-9C51-E778C7AAA1C2Q35865230-F990A10F-832C-4D37-9549-9C4CFACA0B03Q36036244-56A35EAA-7A2A-4B64-8300-7159F733E9A9Q36095063-F57D846C-B882-45C6-AB31-693DFB149AA9Q36711136-07FF6005-3C9E-4BEA-81F3-997D44547F53Q36807640-C8DA47B7-D42C-4BCE-B020-4DA1DD2D25DCQ36842612-EA929631-55D0-493B-BEF8-EE1E31E780EDQ37013424-59F863C6-A4CD-4C5A-976A-C94BB50E8643Q37481309-B6FF37F3-6D83-4608-A2D0-7CB0F0266534Q38067511-46D873BD-1CC2-4B11-A5E6-D0ECA72CA31BQ38160275-C341A597-58E5-4520-B47E-52CE59035AF1Q38308411-1FABA5C2-BE4E-4E1D-8B61-96804488D90CQ38985790-4625DA27-086C-47CC-8DF4-84EC05EB6827Q39345729-856CC0FD-2551-4AA6-9CCA-9CB905E3111CQ39516879-EE2F8582-3CD1-4CD0-900E-727DA1C81569Q39690535-0FC13672-9412-4227-A38C-5442AA23747CQ41877898-1B167F02-262B-4CAA-A3BE-780BBFAB75B0Q41904409-EB75A5D5-D65A-407B-BAC4-92DCB72DC1ADQ42909032-C143A739-5AAE-41E0-8068-AED79F4BF6C0Q45599801-C48F734C-52F3-4B58-8406-AA38C41CA5F7Q50905106-1CD4EF7D-C583-47D5-84F6-E67269BBBB73Q51522567-9B94660C-F353-42AF-BB50-AABD728DBE9C
P2860
Fatty acid receptors as new therapeutic targets for diabetes.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Fatty acid receptors as new therapeutic targets for diabetes.
@ast
Fatty acid receptors as new therapeutic targets for diabetes.
@en
type
label
Fatty acid receptors as new therapeutic targets for diabetes.
@ast
Fatty acid receptors as new therapeutic targets for diabetes.
@en
prefLabel
Fatty acid receptors as new therapeutic targets for diabetes.
@ast
Fatty acid receptors as new therapeutic targets for diabetes.
@en
P2093
P2860
P1476
Fatty acid receptors as new therapeutic targets for diabetes.
@en
P2093
Geetha Vani Rayasam
Joseph Alex Davis
Vamshi Krishna Tulasi
Vinay S Bansal
P2860
P304
P356
10.1517/14728222.11.5.661
P407
P577
2007-05-01T00:00:00Z